Evidence map›Paper›PMID 42328649›Full record

ArticleFrontiers in pharmacology2026

Precision management of cenobamate in drug-resistant epilepsy: integrating pharmacogenetics, therapeutic drug monitoring, and real-world clinical strategies.

Giuseppe d'Orsi, Maria Teresa Di Claudio, Alessia Cafaro, Sebastiano Barco, Marta Robustella, Nicolò Locatelli, Antonella Liantonio, Paola Imbrici, Grazia Ciavarella, Antonio Rinaldi and 5 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Giuseppe d'OrsiNeurology Unit - Epilepsy Center, Fondazione IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotond, Italy.
Maria Teresa Di ClaudioNeurology Unit - Epilepsy Center, Fondazione IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotond, Italy.
Alessia CafaroBiochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analyses, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Sebastiano BarcoBiochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analyses, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Marta RobustellaNeurology Unit - Epilepsy Center, Fondazione IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotond, Italy.
Nicolò LocatelliNeurology Unit - Epilepsy Center, Fondazione IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotond, Italy.
Antonella LiantonioDepartment of Pharmacy - Drug Sciences, University of Bari "Aldo Moro", Bari, Italy.
Paola ImbriciDepartment of Pharmacy - Drug Sciences, University of Bari "Aldo Moro", Bari, Italy.
Grazia CiavarellaMedicina Trasfusionale e Laboratorio Analisi, Fondazione IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy.
Antonio RinaldiMedicina Trasfusionale e Laboratorio Analisi, Fondazione IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy.
Giuseppe FaniaMedicina Trasfusionale e Laboratorio Analisi, Fondazione IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy.
Umberto CostantinoNeurology Unit - Epilepsy Center, Fondazione IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotond, Italy.
Massimo CarellaUOC Genetica Medica, Fondazione IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy.
Giuliana CangemiBiochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analyses, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Giuseppe MiscioMedicina Trasfusionale e Laboratorio Analisi, Fondazione IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cenobamate (CNB) demonstrates high efficacy in drug-resistant focal epilepsy, yet optimal management requires personalized strategies. This exploratory case series describes five patients selected from a cohort of 125 individuals treated with CNB, examining the relationship between pharmacogenetic (PGx) profiles and clinical outcomes. Clinical data and therapeutic drug monitoring (TDM) were integrated with targeted Next-Generation Sequencing of key metabolic genes (UGT2B7, UGT2B4, CYP2E1, CYP2B6, CYP2A6, CYP3A4, CYP2C19) to predict metabolizer phenotypes. Three patients (Cases 1, 3, 4) achieved seizure freedom or ≥50% response at sub-target or target doses (100-200 mg/day

Indexed as

cenobamatedrug-resistant epilepsypharmacogeneticsprecision medicinereal-world evidencetherapeutic drug monitoring

Identifiers

PMID42328649
PMCPMC13275425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.